Insulin Degludec for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Questions for Deliberation: February 12, 2016 Public Meeting

1. For patients with type 1 diabetes mellitus (DM), is the evidence adequate to demonstrate that the net health benefit of treatment with insulin degludec is greater than that of treatment with insulin glargine U100?
   Yes  No

2. Given the available evidence for patients with type 1 DM, what is the care value* of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

3. Given the available evidence for patients with type 1 DM, what is the provisional health system value** of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

4. For patients with type 2 DM on basal-only insulin regimens, is the evidence adequate to demonstrate that the net health benefit of treatment with insulin degludec is greater than that of treatment with insulin glargine U100?
   Yes  No

5. Given the available evidence for patients with type 2 DM who are on basal-only insulin regimens, what is the care value* of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

6. Given the available evidence for patients with type 2 DM who are on basal-only insulin regimens, what is the provisional health system value** of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

7. For patients with type 2 DM who are on basal-bolus insulin regimens, is the evidence adequate to demonstrate that the net health benefit of treatment with insulin degludec is greater than that of treatment with insulin glargine U100?
   Yes  No

8. Given the available evidence for patients with type 2 DM who are on basal-bolus insulin regimens, what is the care value* of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

9. Given the available evidence for patients with type 2 DM who are on basal-bolus insulin regimens, what is the provisional health system value** of treatment with insulin degludec vs. treatment with insulin glargine U100?
   a. Low  b. Intermediate  c. High

* Care value is determined by looking at four elements: comparative clinical effectiveness, incremental costs per outcomes achieved, other benefits or disadvantages, and contextual considerations. Care value represents the long-term perspective, at the individual patient level, on patient benefits and the incremental costs to achieve those benefits.

** Provisional health system value represents a judgment integrating consideration of the long-term care value of a new intervention with an analysis of its potential short-term budget impact if utilization is unmanaged.